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Long‑term outcomes of fully 
covered self‑expandable metal 
stents versus plastic stents 
in chronic pancreatitis
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Seung Woo Park1, Si Young Song1, Jae Hee Cho4* & Seungmin Bang1*
Chronic pancreatitis (CP) related main pancreatic duct (MPD) stricture has been a challenge for 
endoscopists. Fully covered self‑expandable metal stents (FC‑SEMS) has been tried in CP patients, 
but the efficacy and safety are still controversial. Thus, we aim to compare the long‑term clinical 
efficacy of FC‑SEMS vs. plastic stent placement in persistent MPD strictures secondary to CP. Between 
2007 and 2018, 80 chronic pancreatitis patients (58 males, median age 49 years), who underwent 
endoscopic placement of FC‑SEMS (n = 26) and plastic stent (n = 54) for persistent MPD strictures after 
at least 3 months of initial single plastic stenting, were retrospectively analyzed during a median 
follow‑up duration of 33.7 months. As a result, MPD stricture resolution rate was statistically higher 
in FC‑SEMS group (87.0% vs. 42.0%, p < 0.001). Although immediate complications occurred similarly 
(38.5% vs. 37.0%, p = 0.902), spontaneous migration (26.9%) and de novo strictures (23.1%) were 
pronounced delayed complications in FC‑SEMS group. Pain relief during follow‑up was significantly 
higher in FC‑SEMS group (76.9% vs. 53.7%, p = 0.046). The total procedure cost was similar in both 
groups ($1,455.6 vs. $1,596.9, p = 0.486). In comparison with plastic stent, FC‑SEMS placement for 
persistent MPD strictures had favorable long‑term clinical efficacy, with its typical complications like 
spontaneous migration and de novo strictures.
Chronic pancreatitis (CP) is a benign, irreversible, inflammatory pancreatic disorder, which can result in various 
complications including symptomatic main pancreatic duct (MPD) stricture. In fact, MPD stricture occurred in 
up to 47% of CP patients who received endoscopic  treatment1. Endoscopic pancreatic duct (PD) stenting with 
a single plastic stent has been mainly used for treatment of CP patients with symptomatic MPD  strictures2–4. 
However, PD stents cannot be completely removed in approximately one-third of patients because of persistent 
or recurrent  strictures1,4–6. Therefore, patients with unrelenting symptomatic MPD strictures may require regular 
plastic stent exchanges indefinitely. Although surgical intervention is a definitive treatment option with long-term 
pain relief, patients often refuse it because of its invasiveness and associated adverse  events7. Persistent MPD 
strictures after initial plastic stent placement has been a challenge for endoscopists.
Fully covered self-expandable metal stent (FC-SEMS) placement was lately introduced as an investigated 
treatment option for persistent MPD strictures after single plastic  stenting3. FC-SEMS has advantages including 
a larger diameter, longer patency duration, and technical ease to release compared with plastic  stent8,9. Several 
published data have recently demonstrated clinical efficacy of FC-SEMS as a 37–88% pain improvement dur-
ing a 3–4 year follow-up  period10–12. However, these pilot studies occurred at a single medical center, and were 
limited by a small sample size (10–18 patients). To date, no studies have compared FC-SEMS and plastic stent 
placement for symptomatic CP patients with benign MPD  strictures13. Therefore, we aimed to compare the long-
term clinical efficacy of FC-SEMS vs. plastic stent placement in CP patients with persistent MPD strictures after 
at least 3 months of single plastic stenting in two medical institutions.
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Results
Patients’ characteristics and stent feature. Baseline characteristics and stent feature of FC-SEMS and 
plastic stent group were summarized in Table 1. Median age was 49 years old and 58 (72.5%) patients were male. 
The majority of the MPD strictures were located in the pancreas head (n = 62, 77.5%). Other complications of 
CP such as PD stones, pseudocysts, and biliary strictures occurred simultaneously in both groups from the 
beginning, but their incidences were not significantly different between groups. During the median 24.9 and 
36.2 months of follow-up, procedures related to these complications were excluded in following analyses.
For the plastic stent group, the maximum stent diameters were described in Table 1. In fact, we failed to upsize 
the plastic stent diameter in 19 patients (35.2%) in the plastic stent group. The most frequently used length was 
6 cm (n = 9, 34.6%) for FC-SEMS, and 5 cm (n = 18, 33.3%) and 7 cm (n = 17, 31.5%) for plastic stents. The types 
of FC-SEMSs and plastic stents are listed in Supplementary Tables 1 and 2.
Procedure‑related outcomes. Procedure-related outcomes are summarized in Table 2. Technical suc-
cess was achieved in all patients of both groups (100%). The total duration of stent placement was significantly 
shorter in the FC-SEMS group than in the plastic stent group (median 4.9 vs. 7.3 months, p = 0.022). When stent 
placement duration was calculated from the date of initial plastic stenting, not from the index procedure date, 
the median duration for plastic stenting was 10.5 (interquartile range [IQR], 6.0–21.9) months in the plastic 
group.
In the FC-SEMS group, almost all patients (n = 24, 92.3%) removed the stent, with the exception of two 
patients who retained the FC-SEMS until the last follow-up (their FC-SEMS placement duration were 0.4 and 
2.9 months). However, 31.5% of patients in the plastic stent group continued with MPD stenting (p = 0.019). MPD 
stricture resolution was statistically higher in FC-SEMS group (87.0% vs. 42.0%, p < 0.001). (Fig. 1).
Immediate complications after stent insertion occurred similarly in both groups (38.5% vs. 37.0%, p = 0.902). 
One-fourth of the FC-SEMS group developed spontaneous migration with median 3.1 months interval after 
stent insertion, which was more dominant than in the plastic stent group patients (26.9% vs. 3.7%, p = 0.002). 
In addition, other delayed complications such as stent fracture (7.7%) and de novo stricture (23.1%) occurred 
frequently in the FC-SEMS group (p = 0.039 and < 0.001, respectively). Of the six patients who developed de novo 
strictures after FC-SEMS removal, five were asymptomatic while one was clinically manageable with temporary 
plastic stenting for 3.8 months.
Clinical outcomes. Clinical outcomes in both groups are shown in Fig. 2 and Table 3. Two patients without 
clinical success in the plastic stent group were excluded in following analyses. Compared to the FC-SEMS group, 
about 20% of the plastic stent group suffered significantly from pain relapse during stent placement (3.8% vs. 
19.2%, p = 0.066).
The proportion of patients who showed recurrence after stent removal and recurrence-free survival were not 
statistically different between the two groups (27.3% vs. 43.8%, p = 0.587; mean 50.1 vs. 51.7 months, p = 0.646, 
respectively) (Fig. 3). Finally, in our study population, more patients in FC-SEMS group reported experiencing 
pain relief during follow-up without pain relapse or recurrence (76.9% vs. 53.7%, p = 0.046).
Table 1.  Comparison of patients’ characteristics and stent feature. ¶ For the plastic stent group, the maximum 
stent diameters were described. *Including 4 patients with multiple plastic stent placement (n = 3, 7Fr + 7Fr; 
n = 1, 10Fr + 7Fr). Abbreviations: FC-SEMS, fully covered self-expandable metal stent; PS, plastic stent; IQR, 
interquartile range; CBD, common bile duct.
FC-SEMS group (n = 26) Plastic stent group (n = 54) P -value
Age, median (IQR), years 47.0 (40.3—49.3) 57.0 (38.0—65.3) 0.075
Male, No. (%) 19 (73.1) 39 (72.2) 0.936
Etiology
Alcohol/Hereditary/Idiopathic, No. (%) 20 (76.9)/ 4 (15.4)/ 2 (7.7) 35 (64.8)/ 5 (9.3)/ 14 (25.9) 0.144
Location of stricture
Head/Neck, No. (%) 23 (88.5)/ 3 (11.5) 39 (72.7)/ 15 (27.8) 0.103
Combined complication
Pancreatic duct stones, No. (%) 15 (57.7) 22 (40.7) 0.154
Pseudocyst, No. (%) 5 (19.2) 14 (25.9) 0.510
Biliary stricture at distal CBD, No. (%) 4 (15.4) 6 (11.1) 0.588
Follow-up duration, median (IQR), months 24.9 (11.4—57.7) 36.2 (12.7—85.6) 0.237
Stent feature
Diameter¶, No. (%) 8 mm 12 (46.2) 5Fr 12 (22.2)
10 mm 14 (53.8) 7Fr 26 (48.1)
8.5Fr 2 (3.7)
10Fr 14 (25.9)*
Length, cm 4 ~ 8 5 ~ 12
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Cost‑effectiveness analysis. To compare cost-effectiveness of the stents, we calculated total number of 
endoscopic retrograde cholangiopancreatography (ERCP) sessions and summed the total cost of procedures 
(Table 4). Total number of procedures was significantly lower in the FC-SEMS group (median 2 vs. 3, p = 0.014), 
but the mean cost between the two groups ($1,455.6 vs. $1,596.9, p = 0.486) was not different.
Table 2.  Comparison of procedure-related outcomes. ¶ Excluding 3 patients without follow-up 
pancreatography after stent removal. ¶¶ Excluding 4 patients without follow-up pancreatography after stent 
removal. Abbreviations: FC-SEMS, fully covered self-expandable metal stent; IQR, interquartile range; MPD, 
main pancreatic duct.
FC-SEMS group (n = 26) Plastic stent group (n = 54) p-value
Technical success, No (%) 26 (100) 54 (100)  > 0.99
Stent exchange, No (%) 1 (3.8) 25 (46.3)  < 0.001
Exchange interval, median (IQR), months 3.0 6.1 (3.4–7.8)
Stent placement duration, median (IQR), months 4.9 (4.0—6.5) 7.3 (3.7—15.2) 0.022
Stent removal, No (%) 24 (92.3) 37 (68.5) 0.019
Spontaneous migration, No (%) 7 (26.9) 2 (3.7) 0.002
Scheduled removal, No (%) 17 (65.4) 35 (64.8) 0.960
MPD stricture resolution, No (%) 20 (87.0) ¶ 21 (42.0) ¶¶  < 0.001
Immediate complications, No (%) 10 (38.5) 20 (37.0) 0.902
Cholangitis, No (%) 1 (3.8) 2 (3.7) 0.975
Pancreatitis, No (%) 5 (19.2) 11 (20.4) 0.905
Hyperamylasemia, No (%) 6 (23.1) 8 (14.8) 0.362
Perforation, No (%) 0 (0) 1 (1.9) 0.485
Delayed complications
Proximal migration, No (%) 2 (7.7) 1 (1.9) 0.198
Stent malfunction, No (%) 0 (0.0) 2 (3.7) 0.320
Stent fracture, No (%) 2 (7.7) – 0.039
De novo MPD stricture, No (%) 6 (23.1) –  < 0.001
Figure 1.  Fluoroscopic images of endoscopic retrograde pancreatography. Pancreatography shows a pancreatic 
ductal stricture in the head (white arrows) with upstream duct dilatation (a). After 7 months of FC-SEMS 
placement (b), follow-up pancreatography reveals stricture resolution (c). Pancreatography shows a tight 
pancreatic duct stricture in the pancreas head (black arrows) with upstream duct dilatation (d). After 13 months 
of single plastic stent placement (e), follow-up pancreatography reveals stricture resolution (f). Abbreviation: 
FC-SEMS, fully covered self-expandable metal stent.
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Discussion
This was the first study to describe and compare the long-term clinical efficacies of FC-SEMS and plastic stent 
placements in a clinical setting to treat persistent MPD strictures in patients with CP. Although FC-SEMS showed 
typical delayed complications, such as de novo stricture and spontaneous migration, its clinical efficacy showed 
a higher MPD stricture resolution rate and considerable sustained pain relief during follow-up.
Compared to a plastic stent, FC-SEMS has a larger diameter and longer patency. Further, it is technically easier 
to release FC-SEMS than even a single plastic stent owing to its superior “pushability,” with higher flexibility and 
a lower external diameter of the pushing catheter (7 vs. 10 Fr)8,9. Technically, all FC-SEMSs were successfully 
inserted and removed, including three stent fracture cases and two proximal migration cases. Furthermore, the 
Figure 2.  Flowchart for clinical outcomes. Exclusion of patients with failure of additional stenting of remained 
stricture (*n = 2; **n = 3). Abbreviations: FC-SEMS, fully covered self-expandable metal stent; MPD, main 
pancreatic duct.
Figure 3.  Kaplan-Meir estimation of recurrence-free survival after stent removal in the FC-SEMS (n = 22) 
and plastic stent group (n = 32). There were no significant differences in recurrence-free survival between the 
FC-SEMS and plastic stent groups (50.1 (95% CI, 31.2—69.1) vs. 51.7 (95% CI, 28.7—74.7) months, log-rank 
p = 0.646). Abbreviation: FC-SEMS, fully covered self-expandable metal stent; CI, confidence interval.
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larger diameter of FC-SEMS could help improve the MPD stricture. According to previous studies, stricture 
resolution was achieved in 83–100% of patients treated with FC-SEMS9–12,14 and in 9–50% of patients with single 
plastic  stenting5,15–18.
Temporary placement of FC-SEMS, together with surgery and multiple side-by-side plastic stent placement, 
is currently considered to be a treatment option for refractory MPD strictures, which are defined as a sympto-
matic dominant stricture persisting or relapsing after 1 year of single plastic  stenting3. Comparing clinical data 
of FC-SEMS placement for symptomatic MPD strictures in patients with CP (Supplementary Table 3) has several 
complicated and discordant issues. First, clinical indication for FC-SEMS placement varies. Some early studies 
enrolled all symptomatic patients with an MPD stricture, independent of plastic stent placement before FC-
SEMS  insertion9,14. In contrast, other studies, including ours, included only patients with persistent or refractory 
stricture with inclusion criteria of a 3—10,12 or 12-month11 duration of previous plastic stent placement. When 
Table 3.  Comparison of clinical outcomes. † Excluding 2 patients without clinical success. ¶ Excluding 2 
patients with failure of additional stenting for remained stricture. ¶¶ Excluding 3 patients with failure of 
additional stenting for remained stricture. Abbreviations: FC-SEMS, fully covered self-expandable metal stent; 
CI, Confidence interval.
FC-SEMS group (n = 26) Plastic stent group (n = 54) p-value
Clinical success, No (%) 26 (100) 52 (96.3) 0.320
Pain relapse during stent placement, No (%) 1 (3.8) 10 (19.2)† 0.066
Pain relapse interval, median (95% CI), months 2.6 4.1 (1.0—7.3) 0.384
Recurrence, No (%) 6 (27.3) ¶ 14 (43.8) ¶¶ 0.587
Recurrence-free survival, median (95% CI), months 50.1 (31.2- 69.1) 51.7 (28.7 -74.7) 0.646
Pain relief during follow-up, No (%) 20 (76.9) 29 (53.7) 0.046
Table 4.  Comparison of number of procedure and cost analysis. Abbreviations: FC-SEMS, fully covered self-
expandable metal stent; ERCP, endoscopic retrograde cholangiopancreatography.
FC-SEMS group (n = 26) Plastic stent group (n = 54) p-value
Number of ERCP, median (range) 2 (1 ~ 3) 3 (1 ~ 10) 0.014
Total cost, mean (SD), US$ 1455.6 (333.1) 1596.9 (1000.8) 0.486
Figure 4.  Flowchart for the study population. Abbreviation: ERCP, endoscopic retrograde 
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the FC-SEMS group was divided into subgroups before and after a plastic stent indwelling period of 6 months 
in our results, the FC-SEMS group under 6 months of plastic stent indwelling (n = 13, 50.0%) showed compa-
rable clinical efficacy of MPD stricture resolution, recurrence rates, and pain relief during follow-up (91.7% vs. 
81.8%, p = 0.484; 80.0% vs. 66.7%, p = 0.484; 84.6% vs. 69.2%, p = 0.352, respectively) compared to the remainder 
subgroup (n = 13, 50.0%). Because evidence for FC-SEMS is currently lacking, further clinical trials are required 
for the indications and timing of FC-SEMS placement in patients with CP.
Insertion of a single 10-Fr plastic stent for 1 year was recommended as the initial endoscopic therapy for 
MPD  strictures3,19,20. However, achieving the maximum calibration of plastic stenting can be technically dif-
ficult because of the tightness of the MPD stricture. In our study, the diameter of the plastic stent could not be 
increased in 19 (35.2%) patients, and approximately three-quarters (74.1%) of patients retained a single plastic 
stent with a diameter < 8.5 Fr until the last follow-up (Table 1). When we divided the plastic group based on the 
maximum diameter of the plastic stent, the recurrence rate or recurrence-free survival showed no significant 
difference among subgroups (Supplementary Table 4).
Notably, spontaneous migration developed in one-fourth (26.9%) of patients in the FC-SEMS group, and 
other delayed complications, such as stent fracture (7.7%) and de novo stricture (23.1%), were also prevalent 
(p = 0.002, 0.039, and < 0.001, respectively). Reported frequencies of stent migration and de novo strictures 
for FC-SEMS are 15–46% and 16–27%,  respectively10,12,14,21 (Supplementary Table 3). Tringali et al. reported 
that the short 3-cm FC-SEMS may be associated with frequent stent  migrations12, and Oh et al. suggested that 
additional anchoring inner plastic stents help prevent stent  migration11. Anti-migration systems have recently 
been developed and applied to FC-SEMS21,22, but some concerns exist because of its flared end, which may cause 
stent-induced de novo  stricture10,12,14,21.
Our study has several limitations. First, this was a non-randomized retrospective study. Although statistically 
not significant in baseline characteristics, alcohol consumption and other CP complications during follow-up 
may affect the pain aggravation event. In addition, stent features of FC-SEMS and plastic stents were not unified, 
and there was no consistent strategy for choosing FC-SEMS or plastic stents. Some patients treated with plastic 
stents sub-optimally showed less effective clinical outcomes in the plastic stent group. Data maturity issues make 
it difficult to estimate meaningful recurrence-free survival. Finally, we analyzed cost-effectiveness simply result-
ing from our relatively small study population, excluding the length of hospitalization and complication rates.
In conclusion, FC-SEMS placement for persistent MPD stricture in patients with CP had favorable long-term 
clinical efficacy with a higher MPD stricture resolution rate and sustained pain relief during follow-up compared 
to plastic stenting. Typical complications of FC-SEMS, such as de novo stricture and spontaneous migration, 
remain major issues, necessitating further investigations.
Methods
Study population. We retrospectively collected data from symptomatic CP patients with persistent MPD 
strictures after single plastic stent (5-10Fr) placement for at least 3 months in Severance hospital and Gil medical 
center between January 2007 and December 2018. Patients were included according to the following criteria: 
(1) dominant MPD stricture located in pancreatic head and neck; (2) initially treated with single plastic stent 
insertion; (3) persistent MPD stricture with upstream PD dilatation after initial plastic stent removal. Exclusion 
criteria were as follows: (1) obstructive PD stones without dominant MPD stricture; (2) concomitant tumor of 
pancreas and biliary tract; (3) multiple MPD strictures or strictures located at the pancreas body/tail; (4) FC-
SEMS inserted initially; (5) failure of selective MPD cannulation; (6) previous history of PD stenting at another 
hospital; and (7) improved MPD stricture or follow-up loss after initial PD stenting. Finally, 80 CP patients with 
persistent MPD strictures were included in our analysis. According to types of secondary PD stents, those were 
divided into FC-SEMS groups (n = 26) and plastic stent group (n = 54) (Fig. 4).
The study protocol conformed to the ethical guidelines of the 1975 Helsinki Declaration and was approved by 
the institutional review board (IRB) of each institute (Severance Hospital IRB, 4-2019-2196; Gachon University 
Gil Medical Center IRB, GDIRB2019-410). The need for informed consent was waived by ‘Severance Hospital 
Institutional Review Board’ and ‘Gachon University Gil Medical Center Institutional Review Board’ due to the 
retrospective study design.
Procedures. Experienced endoscopists examined ERCP. When MPD stricture was persistent on subsequent 
pancreatography after removal of the first inserted plastic stent, the physician would try to insert a single plastic 
stent with a larger diameter, perform multiple plastic stent stenting, or use a FC-SEMS. If advancing the cath-
eter or introducing the plastic stent and SEMS through the stricture was difficult, a dilating catheter (6–8.5 Fr 
Soehendra dilatation catheter, Cook Medical) and/or balloon dilator (4–6 mm Hurricane Rx balloon dilators, 
Boston Scientific) were/was used. The stent diameter was chosen according to stricture tightness and diameter of 
the upstream-dilated MPD. Stent length was decided based on stricture location and MPD morphology.
Stents were exchanged or removed every 3–6 months after placement. When patient’s pain relieved and MPD 
stricture was disappeared on follow-up pancreatography, stents were removed. Especially in cases of FC-SEMS 
insertion, we did not maintain the FC-SEMS placement for longer than six months. Therefore, if it was necessary 
to insert an additional stent for a remaining stricture or de novo stricture after 6 months of FC-SEMS placement, 
we used a plastic stent.
Follow‑up. Outpatient follow-up was scheduled at 1, 3, and 6 months after stent insertion or exchange. After 
stent removal, follow-up was continued at 6-month intervals or whenever complications occurred. Physicians 
and registered nurses carefully assessed the pain intensity before stent insertion at an outpatient clinic visit, daily 
during hospitalization for procedure, and at each scheduled follow-up outpatient visit. ERCP was considered 
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when the pain was aggravated or when procedure-related complications developed. The last follow-up was per-
formed in June 2019.
Study endpoints. When analyzing procedure-related outcomes, we regarded the second ERCP after initial 
plastic stent removal as an index procedure. Technical success was defined as successful placement of the stents, 
FC-SEMS or plastic stent during index procedures. MPD stricture resolution was defined as a resolved stricture 
with complete runoff of contrast material on the follow-up pancreatography. We also analyzed the immedi-
ate and delayed complications such as proximal or distal migration, stent fracture, and stent-induced de novo 
stricture. Spontaneous migration was defined as radiological or endoscopic evidence of stent disappearance due 
to distal movement away from the stricture. A de novo stricture could develop above the intraductal end of the 
FC-SEMS. Other complications related to ERCP were defined according to the American Society for Gastroin-
testinal Endoscopy  workshop25.
We evaluated clinical outcomes, which were entirely related to patients’ symptoms, in three periods: clinical 
success during index procedure, pain relapse during stent placement, and recurrence after stent removal. Clinical 
success was defined as a > 50% reduction in the visual analog scale (VAS) scale pain score before and after stent 
placement during hospitalization for the index procedure. Recurrence was defined as a > 50% elevation in the VAS 
scale pain score compared with that after stent removal, or pain aggravation causing hospitalization or therapeu-
tic intervention to the MPD stricture. If such pain aggravation occurred during stent placement, we separately 
defined it as ‘pain relapse’, as another parameter of clinical outcomes. Finally, it means that patients with pain 
relief during follow-up did not experience any pain relapse or recurrence after index procedure for PD stenting.
To compare total cost of placing the FC-SEMS and plastic stent, we calculated the sum of expenses of ERCP 
with stent insertion, exchange, and removal, including charges for all FC-SEMS and plastic stents used in both 
groups after index procedure, based on an annual medical fee schedule from Korean National Health  Insurance26. 
These costs were converted from Korean won to U.S. dollars according the annual average exchange rate.
Statistical analysis. Data were expressed as the mean ± standard deviation (SD), median (IQR or range), 
or n (%), as appropriate. A Student’s t-test or Mann–Whitney test was used to analyze continuous variables, and 
a Fisher’s exact test or Pearson’s chi-square test for categorical variables. Survival rates without recurrence were 
estimated and compared using the Kaplan–Meier method and the log-rank test. A two-tailed P-value of < 0.05 
was considered statistically significant. The statistical analysis was performed with SPSS, version 25.0 (PASW 
Statistics Inc., Chicago, IL, USA).
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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